Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16


Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.

Ceresoli GL, Aerts JG, Dziadziuszko R, Ramlau R, Cedres S, van Meerbeeck JP, Mencoboni M, Planchard D, Chella A, Crinò L, Krzakowski M, Rüssel J, Maconi A, Gianoncelli L, Grosso F.

Lancet Oncol. 2019 Oct 15. pii: S1470-2045(19)30532-7. doi: 10.1016/S1470-2045(19)30532-7. [Epub ahead of print]


Brain metastases in EGFR-positive non-small cell lung cancer: the way to the sanctuary becomes less winding.

Passaro A, Gianoncelli L, Stati V, de Marinis F.

Ann Transl Med. 2019 Jul;7(Suppl 3):S80. doi: 10.21037/atm.2019.04.04. No abstract available.


Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study.

Restelli U, Ceresoli GL, Croce D, Evangelista L, Maffioli LS, Gianoncelli L, Bombardieri E.

Cancer Manag Res. 2017 Dec 7;9:789-800. doi: 10.2147/CMAR.S148323. eCollection 2017. Erratum in: Cancer Manag Res. 2018 Mar 27;10 :613.


Prognostic and predictive role of [18 F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy.

Zucali PA, Lopci E, Ceresoli GL, Giordano L, Perrino M, Ciocia G, Gianoncelli L, Lorenzi E, Simonelli M, De Vincenzo F, Setti LR, Bonifacio C, Bonomi M, Bombardieri E, Chiti A, Santoro A.

Cancer Med. 2017 Oct;6(10):2287-2296. doi: 10.1002/cam4.1182. Epub 2017 Sep 21.


Clinical staging of malignant pleural mesothelioma: current perspectives.

Bonomi M, De Filippis C, Lopci E, Gianoncelli L, Rizzardi G, Cerchiaro E, Bortolotti L, Zanello A, Ceresoli GL.

Lung Cancer (Auckl). 2017 Aug 18;8:127-139. doi: 10.2147/LCTT.S102113. eCollection 2017. Review.


Prognostic and predictive value of MET deregulation in non-small cell lung cancer.

Finocchiaro G, Toschi L, Gianoncelli L, Baretti M, Santoro A.

Ann Transl Med. 2015 Apr;3(6):83. doi: 10.3978/j.issn.2305-5839.2015.03.43. Review.


Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma.

Lopci E, Zucali PA, Ceresoli GL, Perrino M, Giordano L, Gianoncelli L, Lorenzi E, Gemelli M, Santoro A, Chiti A.

Eur J Nucl Med Mol Imaging. 2015 Apr;42(5):667-75. doi: 10.1007/s00259-014-2960-y. Epub 2014 Nov 18.


Increased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage disease.

Toschi L, Finocchiaro G, Nguyen TT, Skokan MC, Giordano L, Gianoncelli L, Perrino M, Siracusano L, Di Tommaso L, Infante M, Alloisio M, Roncalli M, Scorsetti M, Jänne PA, Santoro A, Varella-Garcia M.

PLoS One. 2014 Apr 15;9(4):e95303. doi: 10.1371/journal.pone.0095303. eCollection 2014.


Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.

Zucali PA, Perrino M, Lorenzi E, Ceresoli GL, De Vincenzo F, Simonelli M, Gianoncelli L, De Sanctis R, Giordano L, Santoro A.

Lung Cancer. 2014 Jun;84(3):265-70. doi: 10.1016/j.lungcan.2013.11.011. Epub 2013 Nov 20.


Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma.

Ceresoli GL, Zucali PA, Mencoboni M, Botta M, Grossi F, Cortinovis D, Zilembo N, Ripa C, Tiseo M, Favaretto AG, Soto-Parra H, De Vincenzo F, Bruzzone A, Lorenzi E, Gianoncelli L, Ercoli B, Giordano L, Santoro A.

Br J Cancer. 2013 Aug 6;109(3):552-8. doi: 10.1038/bjc.2013.368. Epub 2013 Jul 16.


Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.

Giovannetti E, Zucali PA, Assaraf YG, Leon LG, Smid K, Alecci C, Giancola F, Destro A, Gianoncelli L, Lorenzi E, Roncalli M, Santoro A, Peters GJ.

Br J Cancer. 2011 Nov 8;105(10):1542-53. doi: 10.1038/bjc.2011.400. Epub 2011 Oct 4.


Response to sunitinib in an adult patient with rhabdoid renal cell carcinoma.

De Vincenzo F, Zucali PA, Ceresoli GL, Colombo P, Simonelli M, Lorenzi E, Perrino M, Gianoncelli L, De Sanctis R, Graziotti P, Santoro A.

J Clin Oncol. 2011 Jun 20;29(18):e529-31. doi: 10.1200/JCO.2011.34.8284. Epub 2011 Apr 11. No abstract available.


Advances in the biology of malignant pleural mesothelioma.

Zucali PA, Ceresoli GL, De Vincenzo F, Simonelli M, Lorenzi E, Gianoncelli L, Santoro A.

Cancer Treat Rev. 2011 Nov;37(7):543-58. doi: 10.1016/j.ctrv.2011.01.001. Epub 2011 Feb 1. Review.


Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.

Zucali PA, Giovannetti E, Destro A, Mencoboni M, Ceresoli GL, Gianoncelli L, Lorenzi E, De Vincenzo F, Simonelli M, Perrino M, Bruzzone A, Thunnissen E, Tunesi G, Giordano L, Roncalli M, Peters GJ, Santoro A.

Clin Cancer Res. 2011 Apr 15;17(8):2581-90. doi: 10.1158/1078-0432.CCR-10-2873. Epub 2011 Jan 24.


Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.

Ceresoli GL, Zucali PA, De Vincenzo F, Gianoncelli L, Simonelli M, Lorenzi E, Ripa C, Giordano L, Santoro A.

Lung Cancer. 2011 Apr;72(1):73-7. doi: 10.1016/j.lungcan.2010.12.004. Epub 2011 Jan 8.


Second-line treatment for malignant pleural mesothelioma.

Ceresoli GL, Zucali PA, Gianoncelli L, Lorenzi E, Santoro A.

Cancer Treat Rev. 2010 Feb;36(1):24-32. doi: 10.1016/j.ctrv.2009.09.003. Epub 2009 Oct 29. Review.


Supplemental Content

Loading ...
Support Center